Biosimilar infliximab for Behçet's syndrome: a case series.

Dincses, E.; Esatoglu, S.; Ozguler, Y.; Uygunoglu, U.; Hamuryudan, Vedat; Seyahi, E.; Melikoglu, M.; Fresko, I.; Ucar, Didar; Ozyazgan, Y.; Kutlubay, Z.; Mat, M.; Yurdakul, S.; Siva, A.; Hatemi, G.

Biosimilar infliximab for Behçet's syndrome: a case series.

Atıf İçin Kopyala

Dincses E., Esatoglu S. N., Ozguler Y., Uygunoglu U., Hamuryudan V., Seyahi E., ...Daha Fazla

Clinical and experimental rheumatology, sa.6, ss.111-115, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: Sayı: 6
Basım Tarihi: 2019
Dergi Adı: Clinical and experimental rheumatology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.111-115
İstanbul Üniversitesi Adresli: Evet

Özet

Objective. The efficacy and safety of biosimilar infliximab (bio-IFX) was shown in randomised controlled trials and it was approved for all indications of the reference product in several countries. However, a previous case series of 3 patients with Behcet's syndrome (BS) reported disappointing results. We aimed to share our experience with bio-IFX treatment in different types of organ involvement in patients with BS.